Breaking News

Lonza to Divest Specialty Ingredients Biz

Allows Lonza to focus on its position in the healthcare industry and to accelerate strategic priorities.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lonza has entered into a definitive agreement with Bain Capital and Cinven to to sell its Specialty Ingredients business and operations for an enterprise value of CHF 4.2 billion.   Both Bain Capital and Cinven have experience in the industrials sector and a track record of successful investments in portfolio companies.   Lonza’s Specialty Ingredients business operates across 17 manufacturing sites globally and has approximately 2,800 employees. The business is a leading provider of microbial co...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters